Table of Contents
ABOUT THIS PROFILE
- PharmaVitae Explorer database
- Chapter structure
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales and growth rate performance, 2002 - 14
- Financial performance, 2002 - 14
- Bristol-Myers Squibb: PharmaVitae forecasts at a glance
- Strategic insight
- BMS has the second fastest expiry decline within Big Pharma
- BMS will focus on areas of high unmet need to mitigate the decline of
its CV portfolio
- BMS builds Big Pharma collaborations
- BMS fast evolving into a fully-fledged biopharmaceutical player
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Company announcements
- Future product milestones
COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- Squibb
- Bristol-Myers Squibb
- M&A history
- (Untitled sub-section)
- Corporate restructuring to focus on pharma
COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
- Historical analysis
- Forecast analysis
- Product analysis
- Product analysis, 2002 - 08
- Product analysis, 2008 - 14
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2008 - 14
- Core analysis, 2008 - 14
- Expiry analysis, 2008 - 14
- Launch/core/expiry configuration, 2008 - 14
- Molecule type analysis
- Externalization analysis
COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and
company-reported total sales, 2002 - 08
- Financial statements, 2001 - 07
- Operating costs and profit analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2008 - 14
- Operating costs and profit analysis, 2008 - 14
KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Infectious diseases
- Reyataz
- Sustiva franchise
- Baraclude
- Immunology & inflammation
- Endocrine, metabolic & genetic disorders
- Onglyza
APPENDIX
- Abbreviations
- Exchange rates
TABLES
- Table: Bristol-Myers Squibb - PharmaVitae forecasts at a glance
- Table: Bristol-Myers Squibb' s exposure to Plavix sales ($m), 2008 - 14
- Table: Expiry sales across Big Pharma ($m), 2008 & 2014
- Table: Key Brands within Bristol-Myers Squibb' s prescription portfolio
- Table: Bristol-Myers Squibb key product developments, 2009
- Table: Bristol-Myers Squibb deals and alliances, 2009
- Table: Bristol-Myers Squibb company announcements, 2009
- Table: BMS future product milestones, 2009 - 11
- Table: Bristol-Myers Squibb product portfolio overview ($m), 2002 - 08
- Table: Bristol-Myers Squibb product portfolio overview ($m), 2008 - 14
- Table: Bristol-Myers Squibb prescription pharmaceutical sales by therapy
area ($m), 2008 - 14
- Table: Bristol-Myers Squibb prescription pharmaceutical sales by
geographic region ($m), 2008 - 14
- Table: Bristol-Myers Squibb launch portfolio overview ($m), 2008 - 14
- Table: Bristol-Myers Squibb core portfolio overview ($m), 2008 - 14
- Table: Bristol-Myers Squibb expiry portfolio overview ($m), 2008 - 14
- Table: Bristol-Myers Squibb prescription pharmaceutical sales by molecule
type ($m), 2008 - 14
- Table: Bristol-Myers Squibb prescription pharmaceutical sales by source
($m), 2008 - 14
- Table: Total Bristol-Myers Squibb sales by business unit ($m), 2002 - 08
- Table: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2002 - 08
- Table: Bristol-Myers Squibb operating cost ratio analysis (% of total
revenues), 2002 - 08
- Table: Bristol-Myers Squibb operating cost ratio analysis (% of total
revenues), 2008 - 14
- Table: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2008 - 14
- Table: Key products overview
- Table: Reyataz: overview
- Table: Reyataz: sales forecast ($m), 2008 - 14
- Table: Sustiva franchise: overview
- Table: Sustiva franchise: sales forecast ($m), 2008 - 14
- Table: Baraclude: overview
- Table: Baraclude: sales forecast ($m), 2008 - 14
- Table: Erbitux: overview
- Table: Erbitux: sales forecast ($m), 2008 - 14
- Table: Sprycel: overview
- Table: Sprycel: sales forecast ($m), 2008 - 14
- Table: Ixempra: overview
- Table: Ixempra: sales forecast ($m), 2008 - 14
- Table: Abilify: overview
- Table: Abilify: sales forecast ($m), 2008 - 14
- Table: Orencia: overview
- Table: Orencia: sales forecast ($m), 2008 - 14
- Table: Plavix: overview
- Table: Plavix: sales forecast ($m), 2008 - 14
- Table: Onglyza: overview
- Table: Onglyza: sales forecast ($m), 2008 - 14
- Table: Bristol-Myers Squibb' s R&D pipeline (Phase I - registration)
- Table: Exchange rates, 2009
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: Bristol-Myers Squibb prescription pharmaceutical performance,
sales ($m) and growth rate (%), 2002 - 14
- Figure: Bristol-Myers Squibb' s financial performance ($m), 2002 - 14
- Figure: Bristol-Myers Squibb' s exposure to Plavix ($m), 2002 - 14
- Figure: Bristol-Myers Squibb' s therapeutic focus, 2002 - 14
- Figure: Bristol-Myers Squibb SWOT analysis
- Figure: Bristol-Myers Squibb prescription pharmaceutical performance,
sales ($m) and growth rate (%), 2002 - 14
- Figure: Key product sales ($m), 2002 - 14
- Figure: Bristol-Myers Squibb key sales growth drivers and resistors ($m),
2002 - 08
- Figure: Bristol-Myers Squibb key sales growth drivers and resistors ($m),
2008 - 14
- Figure: Bristol-Myers Squibb prescription pharmaceutical sales by therapy
area ($m), 2002 - 14
- Figure: Bristol-Myers Squibb prescription pharmaceutical sales by
geographic region ($m), 2002 - 14
- Figure: Bristol-Myers Squibb launch/core/expiry configuration ($m), 2008 -
14
- Figure: Bristol-Myers Squibb prescription pharmaceutical sales by molecule
type ($m), 2002 - 14
- Figure: Bristol-Myers Squibb prescription pharmaceutical sales by source
($m), 2002 - 14
- Figure: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2002 -
14
|
Related Report
|
View Cart
